Sandostatin desensitization--a strategy useful for patients with carcinoid tumors, intolerant to sandostatin.

Abstract	Sandostatin immediate release (IR) is frequently used to treat patients with carcinoid tumors. However, some patients are unable to tolerate the immediate side effects of sandostatin IR leading to discontinuation of the drug. There is no literature available to guide the management of patients' sensitivity/intolerance to sandostatin IR. We report a 49-year-old male with carcinoid tumor who was intolerant to sandostatin IR initially but was able to tolerate the drug after we employed a desensitization strategy.
Authors	Sanjay Vinjamaram, Renuka Iyer
Journal	Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 68 Issue 1 Pg. 225-6 (Jul 2011) ISSN: 1432-0843 [Electronic] Germany
PMID	20922390 (Publication Type: Case Reports, Journal Article)
Chemical References	Antineoplastic Agents, Hormonal Octreotide
Topics	Antineoplastic Agents, Hormonal (administration & dosage, adverse effects, therapeutic use) Carcinoid Tumor (drug therapy) Desensitization, Immunologic Humans Male Middle Aged Octreotide (administration & dosage, adverse effects, therapeutic use) Pancreatic Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!